Capital Blue Cross update: CAA Rx Drug Cost Reporting filing
Capital Blue Cross appreciates your continued collaboration as we have worked together to fulfill the Consolidated Appropriations Act’s (CAA) prescription drug data collection (RxDC) requirements. We have submitted data and narrative summaries for commercial group customers to the tri-agencies as follows:
Group Type
Filings submitted
Fully Insured (PPACA, Mid-Market, Large Group)
Small Group ASO
D1–D8, P1, and accompanying P-2 files (aggregated at the group level, consistent with CMS instructions)
Large ASO groups with pharmacy carved in
D1*, D2, D3–D8, and accompanying P2 files directly to CMS (aggregated at the group level, consistent with CMS instructions)
Large ASO groups with pharmacy carved out
D1*, D2, and accompanying P2 files (aggregated at the group level, consistent with CMS instructions)
*Capital provided this service for groups that: 1) asked for assistance to meet their D1 reporting requirements under the CAA; 2) provided Capital their data as directed, and 3) agreed to hold Capital harmless for the accuracy of the data submitted and compliance obligations.
Capital’s reporting on behalf of our Large ASO group customers (both those that carve in and carve out their pharmacy coverage) does not transfer those groups’ compliance obligations to Capital.
Thank you for your collaboration as we work through the complexities of this CAA requirement. We appreciate your business and working with you to help our respective clients and customers.